Patents by Inventor Stephen E. Webber

Stephen E. Webber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR7 AGONISTS
    Publication number: 20240116974
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: June 30, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. WEBBER, James Richard APPLEMAN
  • Crystalline forms of Mnk inhibitors
    Patent number: 11952375
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: April 9, 2024
    Assignee: eFFECTOR Therapeutics Inc.
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • TLR7 agonists
    Patent number: 11692005
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: July 4, 2023
    Assignee: Primmune Therapeutics, Inc.
    Inventors: Stephen E. Webber, James Richard Appleman
  • SARS-3CL PROTEASE INHIBITORS
    Publication number: 20220324800
    Abstract: The present invention relates to antiviral agents according to Formula I and their use in the treatment of viral infection.
    Type: Application
    Filed: March 31, 2022
    Publication date: October 13, 2022
    Inventor: Stephen E. Webber
  • CRYSTALLINE FORMS OF MNK INHIBITORS
    Publication number: 20220119387
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 21, 2022
    Inventors: Siegfried H. REICH, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • SUBSTITUTED PURINES AS TLR7 AGONISTS
    Publication number: 20220098198
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: July 9, 2021
    Publication date: March 31, 2022
    Inventors: Stephen E. Webber, James Richard Appleman
  • MNK INHIBITORS AND METHODS RELATED THERETO
    Publication number: 20210338673
    Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 4, 2021
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. XIANG, Justin T. Ernst
  • Crystalline forms of MNK inhibitors
    Patent number: 11130757
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: September 28, 2021
    Assignee: eFFECTOR Therapeutics Inc.
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • Substituted purines as TLR7 agonists
    Patent number: 11059824
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: July 13, 2021
    Assignee: Primmune Therapeutics, Inc.
    Inventors: Stephen E. Webber, James Richard Appleman
  • TLR7 AGONISTS
    Publication number: 20210155652
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 27, 2021
    Inventors: Stephen E. Webber, James Richard Appleman
  • Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2
    Patent number: 11014926
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: May 25, 2021
    Assignee: eFFECTOR Therapeutics, Inc.
    Inventors: Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E Webber
  • Indoline analogs and uses thereof
    Patent number: 10711008
    Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 14, 2020
    Assignee: Oncternal Therapeutics, Inc.
    Inventor: Stephen E. Webber
  • CRYSTALLINE FORMS OF MNK INHIBITORS
    Publication number: 20200131179
    Abstract: The present invention provides crystalline solids of 6?-((6-aminopyrimidin-4-yl)amino)-8?-methyl-2?H-spiro[cyclohexane-1,3?-imidazo[1,5-a]pyridine]-1?,5?-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Emst, Bennett C. Borer, Samuel Sperry, Jo Ann Z. Wilson
  • TLR7 AGONISTS
    Publication number: 20190359613
    Abstract: The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 28, 2019
    Inventors: Stephen E. Webber, James Richard Appleman
  • INDOLINE ANALOGS AND USES THEREOF
    Publication number: 20190337951
    Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
    Type: Application
    Filed: June 3, 2019
    Publication date: November 7, 2019
    Inventor: Stephen E. Webber
  • PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2
    Publication number: 20190330216
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2. A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b and R10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: April 9, 2019
    Publication date: October 31, 2019
    Inventors: Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E Webber
  • Indoline analogs and uses thereof
    Patent number: 10351569
    Abstract: Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: July 16, 2019
    Assignee: Oncternal Therapeutics, Inc.
    Inventor: Stephen E. Webber
  • MNK INHIBITORS AND METHODS RELATED THERETO
    Publication number: 20190209560
    Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 2, 2018
    Publication date: July 11, 2019
    Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst
  • ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2
    Publication number: 20190152988
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 23, 2019
    Inventors: Paul A. Sprengeler, Siegfried H. Reich, Justin T. Ernst, Stephen E. Webber, Mike Shaghafi, Douglas Murphy, Chinh Tran
  • CK2 inhibitors, compositions and methods thereof
    Patent number: 10227344
    Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: March 12, 2019
    Assignee: Polaris Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Xueliang Tao, Elena Brin